Περίληψη:
Background: Peanut allergy has a rising prevalence in high-income countries, affecting 0.5%–1.4% of children. This study aimed to better understand peanut anaphylaxis in comparison to anaphylaxis to other food triggers in European children and adolescents. Methods: Data was sourced from the European Anaphylaxis Registry via an online questionnaire, after in-depth review of food-induced anaphylaxis cases in a tertiary paediatric allergy centre. Results: 3514 cases of food anaphylaxis were reported between July 2007-March 2018, 56% in patients younger than 18 years. Peanut anaphylaxis was recorded in 459 children and adolescents (85% of all peanut anaphylaxis cases). Previous reactions (42% vs. 38%; p = .001), asthma comorbidity (47% vs. 35%; p < .001), relevant cofactors (29% vs. 22%; p = .004) and biphasic reactions (10% vs. 4%; p = .001) were more commonly reported in peanut anaphylaxis. Most cases were labelled as severe anaphylaxis (Ring&Messmer grade III 65% vs. 56% and grade IV 1.1% vs. 0.9%; p = .001). Self-administration of intramuscular adrenaline was low (17% vs. 15%), professional adrenaline administration was higher in non-peanut food anaphylaxis (34% vs. 26%; p = .003). Hospitalization was higher for peanut anaphylaxis (67% vs. 54%; p = .004). Conclusions: The European Anaphylaxis Registry data confirmed peanut as one of the major causes of severe, potentially life-threatening allergic reactions in European children, with some characteristic features e.g., presence of asthma comorbidity and increased rate of biphasic reactions. Usage of intramuscular adrenaline as first-line treatment is low and needs to be improved. The Registry, designed as the largest database on anaphylaxis, allows continuous assessment of this condition. © 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Συγγραφείς:
Maris, I.
Dölle-Bierke, S.
Renaudin, J.-M.
Lange, L.
Koehli, A.
Spindler, T.
Hourihane, J.
Scherer, K.
Nemat, K.
Kemen, C.
Neustädter, I.
Vogelberg, C.
Reese, T.
Yildiz, I.
Szepfalusi, Z.
Ott, H.
Straube, H.
Papadopoulos, N.G.
Hämmerling, S.
Staden, U.
Polz, M.
Mustakov, T.
Cichocka-Jarosz, E.
Cocco, R.
Fiocchi, A.G.
Fernandez-Rivas, M.
Worm, M.
Network for Online Registration of Anaphylaxis (NORA)
Λέξεις-κλειδιά:
antihistaminic agent; beta 2 adrenergic receptor stimulating agent; corticosteroid; epinephrine; food allergen; epinephrine, adolescent; anaphylaxis; Article; asthma; cashew nut; child; child hospitalization; cohort analysis; comorbidity; disease registry; disease severity; drug self administration; egg allergy; emergency treatment; European; European Anaphylaxis Registry; female; hazelnut; human; major clinical study; male; milk allergy; nut allergy; peanut allergy; preschool child; school child; tertiary care center; anaphylaxis; Arachis; peanut allergy; register, Adolescent; Anaphylaxis; Arachis; Child; Epinephrine; Humans; Peanut Hypersensitivity; Registries
